Autologous hematopoietic stem cell transplantation in Hodgkin's Lymphoma

Authors

  • Calixto Hernández Cruz Hospital Clínico Quirúrgico "Hermanos Ameijeiras"
  • José Carnot Uria HHA
  • Jesús Diego de la Campa
  • Jorge Muñío Perurena
  • Ibis Pardo Ramírez
  • Kali Cepero Llauger
  • Aliette García García

Keywords:

anthology transplant, Hodgkin's lymphoma, mortality, treatment

Abstract

Introduction: Autologous hematopoietic stem cell transplantation is an applicable therapy in certain situations to patients with Hodgkin's Lymphoma.

Objective: To evaluate the response to autologous hematopoietic stem cell transplantation in patients with Hodgkin's Lymphoma. 

Methods: A study of 60 patients with Hodgkin lymphoma transplanted at Hermanos Ameijeiras Clinical and Surgical Hospital was carried out from 1991 to 2018. The percentage of response at three months, overall survival and disease-free survival period were estimated at five years.

Results: The response rate at three months was 82.7%. Overall and disease-free survival at five years was 94.7% and 51.7%, respectively. Early transplant-related mortality was 5%. 

Conclusions: The use of autologous hematopoietic stem cell transplantation was a valid therapeutic alternative. The low early mortality evidenced that the procedure was performed with a satisfactory safety profile.

Downloads

Author Biographies

Calixto Hernández Cruz, Hospital Clínico Quirúrgico "Hermanos Ameijeiras"

jefe servicio hematologia Hospital Hermanos Ameijeiras

José Carnot Uria, HHA

profesor consultate de hematologia HHA

Downloads

Published

2021-03-11

How to Cite

1.
Hernández Cruz C, Carnot Uria J, de la Campa JD, Muñío Perurena J, Pardo Ramírez I, Cepero Llauger K, et al. Autologous hematopoietic stem cell transplantation in Hodgkin’s Lymphoma. Rev Cubana Med [Internet]. 2021 Mar. 11 [cited 2025 Mar. 14];60(2). Available from: https://revmedicina.sld.cu/index.php/med/article/view/2509

Issue

Vol. 60 No. 2 (2021): abril-junio

Section

Original articles

License

The Cuban Journal of Medicine protects the author's patrimonial rights. However, it is licensed under a Creative Commons Licensehttps://creativecommons.org/licenses/by-nc/4.0/deed.es_ES which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided that the primary source of publication is duly cited. The author always retains his moral rights.

 

You are free to:

- Share - copy and redistribute the material in any medium or format.

- Adapt - remix, transform and build upon the material

- The license cannot revoke these freedoms as long as you follow the terms of the license.

Under the following terms:

- Attribution - You must give proper credit, provide a link to the license, and indicate if changes have been made. You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is supported by the licensor.

- Non-Commercial Purpose- You may not make use of the material for commercial purposes.

- No Additional Restrictions - You may not apply legal terms or technological measures that legally restrict others from making any use permitted by the license.